Thursday, September 17, 2020 6:40:18 AM
Danish top manager in violent legal settlement: Can be punished with a fine of two billion
berlingske.dk/virksomheder/dansk-topchef-i-voldsomt-retsopgoer-kan-blive-straffet-med-boede-paa
August 26, 2020
COMPANIES
The pharmaceutical giant Teva, led by Kåre Schultz, denies having done anything wrong in a huge case of price fraud in the USA, where several other copy companies have admitted their guilt and paid large compensation. Now the Danish top manager is on his way into a rare and risky showdown with the US Department of Justice, which could cost the Israeli company a fine of around two billion kroner.
The Danish top manager Kåre Schultz, who heads the Israeli pharmaceutical company Teva, has once again ended up in a heavy legal crisis in the USA. Photo: Amir Cohen / Reuters / Ritzau Scanpix
The Danish pharmaceutical boss Kåre Schultz, who is top manager in Teva, the world's largest producer of counterfeit medicine, is now at the forefront of a huge lawsuit over price fraud with medicines in the USA.
Kåre Schultz and Teva, unlike a number of other pharmaceutical companies, have refused to reach an agreement with the US Department of Justice in a larger case complex, where several companies are accused of having cheated with prices for a number of pharmaceutical preparations.
This means that Teva is heading for a highly unusual legal settlement that could cost the Israeli company fines in the billions.
The US Department of Justice on Tuesday presented three very specific charges against Teva. Each charge could cost the Israeli pharmaceutical company a $ 100 million fine - approx. DKK 630 million - or up to double the amount that Teva must have earned by, as the indictment reads, in collaboration with other companies, having artificially raised the prices of medicines.
"Today's indictment reaffirms that no company is too large to be prosecuted for its role in conspiracies that led to significantly higher prices for generic drugs used by millions of Americans," the statement said. Ministry of Justice.
Teva was founded in 1901, has its global headquarters in Israel and today has around 42,500 employees.
The company has a portfolio of more than 3,500 medical products.
Teva is the world's largest manufacturer of copy medicine and in 2015 completed a gigantic acquisition of competitor Allergan Generics for $ 40.5 billion.
It was this acquisition that made Teva the world's undisputed largest copy company.
At the same time, however, the acquisition has indebted Teva quite heavily. Therefore, under Danish Kåre Schultz, the company embarked on a major horse cure that reduced the copy giant's costs by more than DKK 19 billion over a two-year period.
FOLD OUT
In a statement, Kåre Schultz and Teva flatly deny that the company has done anything wrong. At the same time, the pharmaceutical company declares itself disappointed that the US government has now driven the big legal guns into position.
"The company has been investigating this case for over four years and has concluded that Teva did not participate in the illegal pricing," Teva said.
If the hammer were to end up falling over Teva, Kåre Schultz would be left with a huge challenge, as a gigantic fine from the US Department of Justice is something close to the last thing the 59-year-old medic boss needs.
Because even though Kåre Schultz has succeeded in shrinking a major debt heap in Teva by several billion kroner, it is still the case that the Israeli pharmaceutical company's net debt is about five times as large as operating earnings.
The escalating case of possible price fraud in the USA hits Teva and Kåre Schultz at a time when the company is already struggling with two major lawsuits in particular, which have taken the air out of the Danish top manager's master plan for the rebuilding of the Israeli pharmaceutical giant.
In one lawsuit, Teva is accused of having played a role in a case involving the sale of so-called opioids: a painkiller that, according to US authorities, has created an epidemic crisis in the United States.
In the autumn of 2019, a threatening showdown with more than 2,700 US states, cities and municipalities caused Kåre Schultz and Teva to offer a settlement worth more than DKK 150 billion, which primarily consisted of the value of a certain type of medicine that can detoxify opioid-dependent patients. .
However, that case has not yet been closed.
In another huge lawsuit, Teva is accused of leading a major conspiracy of pharmaceutical companies that for a period from 2013 to 2015 illegally collaborated to raise the prices of their products.
This is at least the claim from a total of 44 US states, which in a 524-page lawsuit have identified Teva as the main culprit in an illegal cartel collaboration, which was coordinated through numerous correspondences by telephone and e-mail and further developed during regular 'industrial dinners'. «, Parties and golf excursions.
All it takes for evil to prevail is for a few good men to do nothing.
Recent AMRN News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM